- Home
- EHI vs LXRX Comparison
EHI vs LXRX Comparison
Compare EHI & LXRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EHI
- LXRX
- Stock Information
- Founded
- EHI 2003
- LXRX 1995
- Country
- EHI United States
- LXRX United States
- Employees
- EHI N/A
- LXRX N/A
- Industry
- EHI Investment Managers
- LXRX Biotechnology: Pharmaceutical Preparations
- Sector
- EHI Finance
- LXRX Health Care
- Exchange
- EHI Nasdaq
- LXRX Nasdaq
- Market Cap
- EHI 194.8M
- LXRX 228.8M
- IPO Year
- EHI N/A
- LXRX 2000
- Fundamental
- Price
- EHI $6.49
- LXRX $1.08
- Analyst Decision
- EHI
- LXRX Buy
- Analyst Count
- EHI 0
- LXRX 4
- Target Price
- EHI N/A
- LXRX $3.67
- AVG Volume (30 Days)
- EHI 44.5K
- LXRX 5.0M
- Earning Date
- EHI 01-01-0001
- LXRX 07-31-2025
- Dividend Yield
- EHI 11.54%
- LXRX N/A
- EPS Growth
- EHI N/A
- LXRX N/A
- EPS
- EHI N/A
- LXRX N/A
- Revenue
- EHI N/A
- LXRX $31,213,000.00
- Revenue This Year
- EHI N/A
- LXRX N/A
- Revenue Next Year
- EHI N/A
- LXRX N/A
- P/E Ratio
- EHI N/A
- LXRX N/A
- Revenue Growth
- EHI N/A
- LXRX 1251.21
- 52 Week Low
- EHI $6.00
- LXRX $0.28
- 52 Week High
- EHI $7.75
- LXRX $2.45
- Technical
- Relative Strength Index (RSI)
- EHI 51.62
- LXRX 66.94
- Support Level
- EHI $6.49
- LXRX $0.84
- Resistance Level
- EHI $6.58
- LXRX $1.19
- Average True Range (ATR)
- EHI 0.05
- LXRX 0.09
- MACD
- EHI -0.00
- LXRX 0.02
- Stochastic Oscillator
- EHI 54.70
- LXRX 76.60
About EHI Western Asset Global High Income Fund Inc
Western Asset Global High Inc Fd Inc is a non-diversified, closed-end management investment company. Its investment objective is high current income and total return by investing in a world-wide portfolio of securities. The fund invests in various sectors such as Consumer Discretionary, Energy, Healthcare, Industrials, materials, and others.
About LXRX Lexicon Pharmaceuticals Inc.
Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, also developing LX9851, an orally-delivered small molecule drug candidate, as a treatment for obesity and associated cardiometabolic.